Literature DB >> 17216414

[Therapy and prognosis of bacterial keratitis].

W Behrens-Baumann1, U Pleyer.   

Abstract

This review discusses the current therapy for bacterial keratitis, especially that using quinolones of the fourth generation. In addition, the importance of additive steroids is discussed. Steroids should be administered at a low dose and tapered off slowly, whereas antibiotics should be applied at a high dosage and discontinued abruptly.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17216414     DOI: 10.1007/s00347-006-1464-y

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  61 in total

1.  [Penetrating re-keratoplasty a chaud using healon 5 for stabilizing the anterior chamber].

Authors:  K Schmitz; W Behrens-Baumann
Journal:  Ophthalmologe       Date:  2000-08       Impact factor: 1.059

2.  Effect of gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions on human corneal epithelium following 2 dosing regimens.

Authors:  Marianne O Price; Francis W Price; David Maclellan
Journal:  J Cataract Refract Surg       Date:  2005-11       Impact factor: 3.351

Review 3.  In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%, a new topical fluoroquinolone.

Authors:  David W Stroman; Joseph J Dajcs; Gale A Cupp; Barry A Schlech
Journal:  Surv Ophthalmol       Date:  2005-11       Impact factor: 6.048

4.  Loading doses and extended dosing intervals in topical gentamicin therapy.

Authors:  D B Glasser; S Gardner; J G Ellis; T H Pettit
Journal:  Am J Ophthalmol       Date:  1985-03-15       Impact factor: 5.258

5.  Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers. Ciprofloxacin Bacterial Keratitis Study Group.

Authors:  R A Hyndiuk; R A Eiferman; D R Caldwell; G O Rosenwasser; C I Santos; H R Katz; S S Badrinath; M K Reddy; J P Adenis; V Klauss
Journal:  Ophthalmology       Date:  1996-11       Impact factor: 12.079

6.  Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous.

Authors:  Seenu M Hariprasad; Kevin J Blinder; Gaurav K Shah; Rajendra S Apte; Brett Rosenblatt; Nancy M Holekamp; Matthew A Thomas; William F Mieler; Jingduan Chi; Randall A Prince
Journal:  Arch Ophthalmol       Date:  2005-01

7.  Efficacy of ofloxacin vs cefazolin and tobramycin in the therapy for bacterial keratitis. Report from the Bacterial Keratitis Study Research Group.

Authors:  T P O'Brien; M G Maguire; N E Fink; E Alfonso; P McDonnell
Journal:  Arch Ophthalmol       Date:  1995-10

Review 8.  Use of corticosteroids in combination with antimicrobial drugs in the treatment of infectious corneal disease.

Authors:  G A Stern; M Buttross
Journal:  Ophthalmology       Date:  1991-06       Impact factor: 12.079

Review 9.  The use of fluoroquinolones in children.

Authors:  Eugene Leibovitz
Journal:  Curr Opin Pediatr       Date:  2006-02       Impact factor: 2.856

10.  Topically administered corticosteroids: effect on antibiotic-treated bacterial keratitis.

Authors:  H M Leibowitz; A Kupferman
Journal:  Arch Ophthalmol       Date:  1980-07
View more
  5 in total

1.  [Introduction to the topic: bacterial keratitis. From the proven to the new].

Authors:  U Pleyer; W Behrens-Baumann
Journal:  Ophthalmologe       Date:  2007-01       Impact factor: 1.059

2.  [Rational antibiotic therapy in ophthalmology].

Authors:  W Behrens-Baumann; U Frank; T Ness
Journal:  Ophthalmologe       Date:  2010-04       Impact factor: 1.059

3.  [Adjunctive corticosteroids for antimicrobial treatment].

Authors:  W Behrens-Baumann
Journal:  Ophthalmologe       Date:  2016-11       Impact factor: 1.059

Review 4.  [Keratomycosis: diagnosis and therapy].

Authors:  W Behrens-Baumann
Journal:  Ophthalmologe       Date:  2009-05       Impact factor: 1.059

5.  [Effectiveness of initial antibiotic therapy for treatment of contact lens-related bacterial keratitis].

Authors:  B Steger; L Speicher; W Philipp; T Gasser; E Schmid; N Bechrakis
Journal:  Ophthalmologe       Date:  2014       Impact factor: 1.059

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.